Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?
Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.
Is Butterfly Medical’s prostate retraction device the next challenger in minimally invasive BPH treatment?
BPH care needs options beyond pills and surgery. Butterfly Medical’s $21m raise puts its reversible prostate implant in the spotlight.
Can ProVee change how BPH is treated? FDA nod gives ProVerum its biggest win yet
ProVerum wins FDA approval for ProVee, a permanent urethral stent for BPH offering fast recovery and no catheter. See how it could disrupt the urology device market.